Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Judith L Anderson"'
Autor:
Daniela N Petrusca, Denise Toscani, Feng-Ming Wang, Cheolkyu Park, Colin D Crean, Judith L Anderson, Silvia Marino, Khalid S Mohammad, Dan Zhou, Rebecca Silbermann, Quanhong Sun, Noriyoshi Kurihara, Deborah L Galson, Nicola Giuliani, G David Roodman
Publikováno v:
Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-14 (2018)
Abstract Background In spite of major advances in treatment, multiple myeloma (MM) is currently an incurable malignancy due to the emergence of drug-resistant clones. We previously showed that MM cells upregulate the transcriptional repressor, growth
Externí odkaz:
https://doaj.org/article/208324c0cf064ed1a922de5482666482
Autor:
Silvia Marino, Daniela N. Petrusca, Ryan T. Bishop, Judith L. Anderson, Hayley M. Sabol, Cody Ashby, Justin H. Layer, Annamaria Cesarano, Utpal P. Davé, Fabiana Perna, Jesus Delgado-Calle, John M. Chirgwin, G. David Roodman
Publikováno v:
Haematologica, Vol 109, Iss 5 (2023)
Multiple myeloma (MM) is a malignancy of plasma cells whose antibody secretion creates proteotoxic stress relieved by the N-end rule pathway, a proteolytic system that degrades N-arginylated proteins in the proteasome. When the proteasome is inhibite
Externí odkaz:
https://doaj.org/article/9399ee6ec7fd4afdb54ee2c23dc3ce56
Autor:
Hayley M. Sabol, G. David Roodman, Noriyoshi Kurihara, Frank H. Ebetino, Venkat Srinivasan, Jesus Delgado-Calle, Kevin McAndrews, Pedro L Cuevas, Adam J. Ferrari, Rajwinder Lehal, Robert K. Boeckman, Sharmin Khan, Manish Adhikari, Judith L. Anderson, Meloney Cregor, Michele Vigolo, Jill A. Helms, Tânia Amorim, Teresita Bellido
Publikováno v:
Cancer Res
Systemic inhibition of Notch with γ-secretase inhibitors (GSI) decreases multiple myeloma tumor growth, but the clinical use of GSI is limited due to its severe gastrointestinal toxicity. In this study, we generated a GSI Notch inhibitor specificall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f2c50e1920d5207f24b5285fa0d42df
https://doi.org/10.1158/0008-5472.can-21-0524
https://doi.org/10.1158/0008-5472.can-21-0524
Autor:
Daniela N, Petrusca, Patrick L, Mulcrone, David A, Macar, Ryan T, Bishop, Evgeny, Berdyshev, Attaya, Suvannasankha, Judith L, Anderson, Quanhong, Sun, Philip E, Auron, Deborah L, Galson, G David, Roodman
Publikováno v:
Cancers. 14(3)
Multiple myeloma (MM) remains incurable for most patients due to the emergence of drug resistant clones. Here we report a p53-independent mechanism responsible for Growth Factor Independence-1 (GFI1) support of MM cell survival by its modulation of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::60a8b67f5ac6fb49ba39449d8c050897
https://pubmed.ncbi.nlm.nih.gov/35159039
https://pubmed.ncbi.nlm.nih.gov/35159039
Autor:
Daniela N. Petrusca, Patrick L. Mulcrone, David A. Macar, Ryan T. Bishop, Evgeny Berdyshev, Attaya Suvannasankha, Judith L. Anderson, Quanhong Sun, Philip E. Auron, Deborah L. Galson, G. David Roodman
Publikováno v:
Cancers; Volume 14; Issue 3; Pages: 772
Cancers, Vol 14, Iss 772, p 772 (2022)
Cancers, Vol 14, Iss 772, p 772 (2022)
Multiple myeloma (MM) remains incurable for most patients due to the emergence of drug resistant clones. Here we report a p53-independent mechanism responsible for Growth Factor Independence-1 (GFI1) support of MM cell survival by its modulation of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34b02a9388d31c1eead24805a7bfca78
https://doi.org/10.3390/cancers14030772
https://doi.org/10.3390/cancers14030772
Autor:
Deborah L. Galson, Daniela N. Petrusca, Judith L. Anderson, Rebecca Silbermann, Feng-Ming Wang, Quanhong Sun, Nicola Giuliani, Khalid S. Mohammad, Cheolkyu Park, Noriyoshi Kurihara, Dan Zhou, Silvia Marino, Denise Toscani, Colin D. Crean, G. David Roodman
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-14 (2018)
Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-14 (2018)
Background In spite of major advances in treatment, multiple myeloma (MM) is currently an incurable malignancy due to the emergence of drug-resistant clones. We previously showed that MM cells upregulate the transcriptional repressor, growth factor i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24feac011431876f5ba1b14da5a5c955
http://europepmc.org/articles/PMC6172782
http://europepmc.org/articles/PMC6172782
Autor:
Juraj Adamik, Xiang-Qun Xie, Deborah L. Galson, Dan Zhou, Judith L. Anderson, G. David Roodman, Silvia Marino, Quanhong Sun, Rebecca Silbermann
Publikováno v:
Frontiers in Endocrinology, Vol 9 (2018)
Multiple myeloma bone disease (MMBD) is characterized by non-healing lytic bone lesions that persist even after a patient has achieved a hematologic remission. We previously reported that p62 (sequestosome-1) in bone marrow stromal cells (BMSC) is cr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d478ea63d4acd039cec0395bc98bbcc
https://doi.org/10.3389/fendo.2018.00344
https://doi.org/10.3389/fendo.2018.00344
Autor:
Jolene J. Windle, Jan H. Beumer, G. D. Roodman, Jumpei Teramachi, Rentian Feng, Julie L. Eiseman, W. Zhao, Noriyoshi Kurihara, Peng Yang, Rebecca Silbermann, Khalid S. Mohammad, Dan Zhou, Judith L. Anderson, Xiang-Qun Xie, Jianxia Guo, Kyaw Z. Myint, N. Maertz
Publikováno v:
Leukemia
We reported that p62 (sequestosome 1) serves as a signaling hub in bone marrow stromal cells (BMSCs) for the formation of signaling complexes, including NFκB, p38MAPK and JNK, that are involved in the increased osteoclastogenesis and multiple myelom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::517354bf398d66169d8f5d6473bbc173
https://doi.org/10.1038/leu.2015.229
https://doi.org/10.1038/leu.2015.229
Autor:
Lilian I. Plotkin, G D Roodman, S A Kuhstoss, Teresita Bellido, Judith L. Anderson, Jesus Delgado-Calle, Meloney Cregor, K W Condon
Publikováno v:
Leukemia
Multiple myeloma (MM) causes lytic bone lesions due to increased bone resorption and concomitant marked suppression of bone formation. Sclerostin (Scl) levels, an osteocyte-derived inhibitor of Wnt/β-catenin signaling, are elevated in MM patient ser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5947f94461846489b45f68978caa433
https://pubmed.ncbi.nlm.nih.gov/28529307
https://pubmed.ncbi.nlm.nih.gov/28529307
Autor:
Deborah L. Galson, Quanhong Sun, Kurt R. Weiss, Shunqian Jin, G. David Roodman, Judith L. Anderson, Juraj Adamik, Rebecca Silbermann, Peng Zhang
In multiple myeloma, osteolytic lesions rarely heal because of persistent suppressed osteoblast differentiation resulting in a high fracture risk. Herein, chromatin immunoprecipitation analyses reveal that multiple myeloma cells induce repressive epi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d81d5d55bb4ad29617e40dd8a9b7907
https://europepmc.org/articles/PMC5524543/
https://europepmc.org/articles/PMC5524543/
